ADC Therapeutics SA

04/23/2021 | Press release | Distributed by Public on 04/23/2021 12:43

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma